Skip to content

Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)

Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03407755
Enrollment
104
Registered
2018-01-23
Start date
2017-09-15
Completion date
2020-05-01
Last updated
2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous Keratopathy, Fuchs' Endothelial Dystrophy

Keywords

Intraocular gas, Positioning, DMEK, Endothelial keratoplasty

Brief summary

This blinded, randomized study compares the use of air and sulfur hexaflouride (SF6) tamponade in Descemet Membrane Endothelial Keratoplasty.

Interventions

PROCEDUREIntraocular gas

Participants randomized to either air or SF6 gas in the anterior chamber.

Sponsors

Glostrup University Hospital, Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Surgeon and patient masked to choice of intraocular gas. Study coordinator not masked.

Intervention model description

Patients randomized to either air or sulfur hexafluoride (SF6)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Eligible for DMEK surgey

Exclusion criteria

Related to ocular health * Re-DMEK or prior penetrating keratoplasty * Ocular hypertension resistant to topical medication * Previous vitrectomy * Minimally invasive glaucoma devices * Aphakia * Anterior chamber or iris claw lens * Implantable Collamer Lens (ICL) * Clinically significant corneal scarring * Central corneal thickness \>750 µm * BCVA \< 0.1 Related to general health * Not able to give informed consent * Inability to position correctly due to organic or psychological condition. Related to surgical procedure * Graft diameter \>9 mm or \< 7mm * Graft central endothelial cell count \< 2000 cells/mm2 * Graft unfolding duration \>1 hour * Graft morphology grade 4-5 * Significant graft decentration (graft contour not visible in microscope) * Significant presence of Descemet remnants in the graft-host interface * Presence of inward folds * Graft 'stroma-surface' placed facing away from recipient stroma

Design outcomes

Primary

MeasureTime frameDescription
Graft detachmentOccurence within 3 months postoperativeSignificant graft detachment: 1/3 of graft and affecting visual function. Measured by OCT.

Secondary

MeasureTime frameDescription
Visual acuity3 months postoperativeSnellen chart (logMAR)
Gas fillSerial measurements during postoperative week 1.Postoperative gas fill measured by OCT.
Positioning72 hours postoperativePitch and roll of head using positioning device
ComplicationsOccurence within 3 months postoperativeAny adverse outcome affecting the eye

Countries

Denmark

Contacts

Primary ContactMark Alberti, MD
malb0038@regionh.dk+4538634823

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026